ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway

Virchows Archiv

Volumn 464, Issue 1, 2014, Pages 53-60

  Calderaro, Julien ^a,b,c   Nault, Jean Charles ^a,c   Bioulac Sage, Paulette ^a,d   Laurent, Alexis ^b,e   Blanc, Jean Frédéric ^d   Decaens, Thomas ^b,e   Zucman Rossi, Jessica ^a,c  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL PELLEGRIN   (France)

^e INSERM U955   (France)

Author keywords

ALDH3A1; CTNNB1; Hepatocellular carcinoma; Wnt beta catenin

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; ALDEHYDE DEHYDROGENASE 3A1; BETA CATENIN; GLUTAMATE AMMONIA LIGASE; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; ARTICLE; DISEASE MARKER; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PRIORITY JOURNAL; TUMOR RECURRENCE;

EID: 84893642718     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1515-0     Document Type: Article

References (36)

1. Muzio G, Maggiora M, Paiuzzi E et al (2012) Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52:735-746. doi: 10.1016/j. freeradbiomed.2011.11.033
2. Chen Y, Thompson DC, Koppaka V et al (2012) Ocular aldehyde dehydrogenases: rotection against ultraviolet damage and maintenance of transparency for vision. Prog Retin Eye Res 33:28-39. doi: 10.1016/j.preteyeres. 2012.10.001
3. Kiefer FW, Orasanu G, Nallamshetty S et al (2012) Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. Endocrinology 153:3089-3099. doi: 10.1210/en.2011-2104
4. Charafe-Jauffret E, Ginestier C, Iovino F et al (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16:45-55. doi: 10.1158/1078-0432.CCR-09-1630
5. Li X, Wan L, Geng J et al (2012) Aldehyde dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J Thorac Oncol 7:1235-1245. doi: 10.1097/JTO.0b013e318257cc6d
6. Luo Y, Dallaglio K, Chen Y et al (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30:2100-2113. doi: 10.1002/stem.1193
7. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
8. Moreb JS, Baker HV, Chang L-J et al (2008) ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 7:87. doi: 10.1186/1476-4598-7-87
9. Muzio G, Trombetta A, Maggiora M et al (2006) Arachidonic acid suppresses growth of human lung tumor A549 cells through down-regulation of ALDH3A1 expression. Free Radic Biol Med 40:1929-1938. doi: 10.1016/j.freeradbiomed.2006. 01.020
10. Muzio G, Canuto RA, Trombetta A, Maggiora M (2001) Inhibition of cytosolic class 3 aldehyde dehydrogenase by antisense oligonucleotides in rat hepatoma cells. Chem Biol Interact 130-132:219-225
11. Duong H-Q, Hwang JS, Kim HJ et al (2012) Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. Int J Oncol 41:855-861. doi: 10.3892/ijo.2012.1516
12. Huang C-P, Tsai M-F, Chang T-H et al (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328:144-151. doi: 10.1016/j.canlet.2012.08.021
13. Khoury T, Ademuyiwa FO, Chandrasekhar R et al (2012) Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol 25:388-397. doi: 10.1038/modpathol.2011.172
14. Schäfer A, Teufel J, Ringel F et al (2012) Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma. Neuro-oncology 14:1452-1464. doi: 10.1093/neuonc/nos270
15. Shibuya A, Takeuchi A, Shibata H et al (1994) Immunohistochemical study of hepatocellular carcinoma-specific aldehyde dehydrogenase. Alcohol Alcohol Suppl 29:119-123
16. Boyault S, Rickman DS, de Reyniès A et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52. doi: 10.1002/hep.21467
17. Nault J-C, Zucman-Rossi J (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31:173-187. doi: 10.1055/s-0031-1276646
18. Guichard C, Amaddeo G, Imbeaud S et al (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44:694-698. doi: 10.1038/ng.2256
19. Thompson MD, Monga SPS (2007) WNT/beta-catenin signaling in liver health and disease. Hepatology 45:1298-1305. doi: 10.1002/hep.21651
20. Zucman-Rossi J, Jeannot E, Nhieu JTV et al (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43:515-524. doi: 10.1002/hep.21068
21. Nault J-C, Bioulac-Sage P, Zucman-Rossi J (2013) Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144:888-902. doi: 10.1053/j.gastro.2013.02.032
22. Nault JC, Fabre M, Couchy G et al (2011) GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. doi: 10.1016/j.jhep.2011.07.018
23. Calderaro J, Labrune P, Morcrette G et al (2012) Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol. doi: 10.1016/j.jhep.2012.09.030
24. Decaens T, Godard C, de Reyniès A et al (2008) Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47:247-258. doi: 10.1002/hep.21952
25. Huang EH, Hynes MJ, Zhang T et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382-3389. doi: 10.1158/0008-5472.CAN-08-4418
26. Sullivan JP, Spinola M, Dodge M et al (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70:9937-9948. doi: 10.1158/0008-5472.CAN-10-0881
27. Fleischman AG (2012) ALDH marks leukemia stem cell. Blood 119:3376-3377. doi: 10.1182/blood-2012-02-406751
28. Audard V, Grimber G, Elie C et al (2007) Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 212:345-352. doi: 10.1002/path.2169
29. Sládek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49:309-321. doi: 10.1007/s00280-001-0412-4
30. Moreb JS, Mohuczy D, Muhoczy D et al (2007) RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 59:127-136. doi: 10.1007/s00280-006-0233-6
31. Hu G, Chong RA, Yang Q et al (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15:9-20. doi: 10.1016/j.ccr.2008.11.013
32. Nault J-C, De Reyniès A, Villanueva A et al (2013) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145:176-187. doi: 10.1053/j.gastro.2013.03. 051
33. Hsu HC, Jeng YM, Mao TL et al (2000) Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 157:763-770
34. Hoshida Y, Toffanin S, Lachenmayer A et al (2010) Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 30:35-51. doi: 10.1055/s-0030-1247131
35. Villanueva A, Hoshida Y, Battiston C et al (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140:1501-1512.e2. doi: 10.1053/j.gastro.2011.02.006
36. Lachenmayer A, Alsinet C, Savic R et al (2012) Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18:4997-5007. doi: 10.1158/1078-0432.CCR-11-2322